Author of

• 25950

  +

  P2.13 - Targeted Therapy (Not CME Accredited Session) (ID 962)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 27191

    +

    P2.13-17 - Non-Small Cell Lung Cancer in the Very Young: More EGFR/ALK Mutation Rate Than the Elder (ID 12589)

    16:45 - 18:00  |  Presenting Author(s): ChienHui He
    • Abstract
    • Slides

    Background
    

    Lung cancer was the leading cause of cancer in worldwise1. Although it remains a disease of older patients, there is a subset of patients who are diagnosed at younger age, such as blow 40 year old. Several studies had shown that the younger group had more females, more non-smokers, more advanced stages of disease, and better survive rate. However, most of these studies didn’t include tumor EGFR/ALK mutation data, especially for the younger group. We retrospectively studied the clinical difference between the younger and the older in patients, including pathologic type, treatment characteristics, and EGFR/ALK mutation status.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    We retrospective reviewed data of NSCLC patients diagnosed during Jun. 2007 to Dec. 2014, and whose age was less than 90 year-old. at Taipei Veterans General Hospital(TPEVGH).

    4c3880bb027f159e801041b1021e88e8 Result
    

    

    There were 5,051 cases of NSCLC, including 168 patients who were <40 years old (younger group) and 4,883 patients aged 40 years or older (older group). It was found younger group had significantly higher EGFR mutation rate than older group (22.6% VS 16.2%, p=0.026), and ALK mutation (4.2% VS 0.5%, p<0.001). Although the younger group had more stage IV patients (60.1% VS 49.6%, p=0.002), they had better (one year:73.7% VS 66.2%, five year:44.4% VS 33.7%) overall survival rate(OS) ( median survival time: 55 VS 26 months ,p=0.002). Regarding histologic subtype, younger group had less squamous cell carcinoma (4.2% VS 16.1% , p<0.001), while adenocarcinoma subtype was similar between two groups (76.8% VS 76.5%, p=0.924).

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Overall survival rate in younger NSCLC patients were better than the older ones. This survival benefit most likely due to higher EGFR mutation and ALK mutation rate and corresponding TKI treatment. Although more advanced-stage NSCLC patients were seen in the younger group at the same time.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.